UNLABELLED: The immunoglobulin superfamily member 1 (IGSF1) gene encodes a plasma membrane glycoprotein mainly expressed in pituitary and testes. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism (CeH), macroorchidism, and delayed puberty (delayed rise of testosterone, but normal timing of testicular growth). As this syndrome was discovered in patients with CeH, it is unknown whether IGSF1 mutations might also cause delayed puberty without CeH. We therefore determined the prevalence of IGSF1 sequence variants in 30 patients with an apparent X-linked form of constitutional delay of growth and puberty (CDGP). In four families, we discovered three novel variants of unknown clinical significance (VUCSs), with possible pathogenicity predicted by in silico analysis. However, the genotype did not fully cosegregate with CDGP, all three VUCSs showed normal plasma membrane expression in transfected HEK293 cells, and no other features of the IGSF1 deficiency syndrome were observed in family members carrying the VUCSs. The observation of hyperprolactinemia in two carriers remains unexplained. CONCLUSION: There is insufficient evidence to conclude that the three observed VUCSs in IGSF1 are associated with CDGP, making it unlikely that IGSF1 mutations are a prevalent cause of CDGP.
UNLABELLED: The immunoglobulin superfamily member 1 (IGSF1) gene encodes a plasma membrane glycoprotein mainly expressed in pituitary and testes. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism (CeH), macroorchidism, and delayed puberty (delayed rise of testosterone, but normal timing of testicular growth). As this syndrome was discovered in patients with CeH, it is unknown whether IGSF1 mutations might also cause delayed puberty without CeH. We therefore determined the prevalence of IGSF1 sequence variants in 30 patients with an apparent X-linked form of constitutional delay of growth and puberty (CDGP). In four families, we discovered three novel variants of unknown clinical significance (VUCSs), with possible pathogenicity predicted by in silico analysis. However, the genotype did not fully cosegregate with CDGP, all three VUCSs showed normal plasma membrane expression in transfected HEK293 cells, and no other features of the IGSF1 deficiency syndrome were observed in family members carrying the VUCSs. The observation of hyperprolactinemia in two carriers remains unexplained. CONCLUSION: There is insufficient evidence to conclude that the three observed VUCSs in IGSF1 are associated with CDGP, making it unlikely that IGSF1 mutations are a prevalent cause of CDGP.
Authors: J Goede; W W M Hack; K Sijstermans; L M van der Voort-Doedens; T Van der Ploeg; A Meij-de Vries; H A Delemarre-van de Waal Journal: Horm Res Paediatr Date: 2011-04-05 Impact factor: 2.852
Authors: Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev Journal: Nat Methods Date: 2010-04 Impact factor: 28.547
Authors: Yu Sun; Beata Bak; Nadia Schoenmakers; A S Paul van Trotsenburg; Wilma Oostdijk; Peter Voshol; Emma Cambridge; Jacqueline K White; Paul le Tissier; S Neda Mousavy Gharavy; Juan P Martinez-Barbera; Wilhelmina H Stokvis-Brantsma; Thomas Vulsma; Marlies J Kempers; Luca Persani; Irene Campi; Marco Bonomi; Paolo Beck-Peccoz; Hongdong Zhu; Timothy M E Davis; Anita C S Hokken-Koelega; Daria Gorbenko Del Blanco; Jayanti J Rangasami; Claudia A L Ruivenkamp; Jeroen F J Laros; Marjolein Kriek; Sarina G Kant; Cathy A J Bosch; Nienke R Biermasz; Natasha M Appelman-Dijkstra; Eleonora P Corssmit; Guido C J Hovens; Alberto M Pereira; Johan T den Dunnen; Michael G Wade; Martijn H Breuning; Raoul C Hennekam; Krishna Chatterjee; Mehul T Dattani; Jan M Wit; Daniel J Bernard Journal: Nat Genet Date: 2012-11-11 Impact factor: 38.330
Authors: S D Joustra; N Schoenmakers; L Persani; I Campi; M Bonomi; G Radetti; P Beck-Peccoz; H Zhu; T M E Davis; Y Sun; E P Corssmit; N M Appelman-Dijkstra; C A Heinen; A M Pereira; A J Varewijck; J A M J L Janssen; E Endert; R C Hennekam; M P Lombardi; M M A M Mannens; B Bak; D J Bernard; M H Breuning; K Chatterjee; M T Dattani; W Oostdijk; N R Biermasz; J M Wit; A S P van Trotsenburg Journal: J Clin Endocrinol Metab Date: 2013-10-09 Impact factor: 5.958
Authors: Fabio R Faucz; Anelia D Horvath; Monalisa F Azevedo; Isaac Levy; Beata Bak; Ying Wang; Paraskevi Xekouki; Eva Szarek; Evgenia Gourgari; Allison D Manning; Rodrigo Bertollo de Alexandre; Emmanouil Saloustros; Giampaolo Trivellin; Maya Lodish; Paul Hofman; Yvonne C Anderson; Ian Holdaway; Edward Oldfield; Prashant Chittiboina; Maria Nesterova; Nienke R Biermasz; Jan M Wit; Daniel J Bernard; Constantine A Stratakis Journal: Endocr Relat Cancer Date: 2014-12-19 Impact factor: 5.678
Authors: Marc-Olivier Turgeon; Tanya L Silander; Denica Doycheva; Xiao-Hui Liao; Marc Rigden; Luisina Ongaro; Xiang Zhou; Sjoerd D Joustra; Jan M Wit; Mike G Wade; Heike Heuer; Samuel Refetoff; Daniel J Bernard Journal: Endocrinology Date: 2017-04-01 Impact factor: 4.736
Authors: S D Joustra; C A Heinen; N Schoenmakers; M Bonomi; B E P B Ballieux; M-O Turgeon; D J Bernard; E Fliers; A S P van Trotsenburg; M Losekoot; L Persani; J M Wit; N R Biermasz; A M Pereira; W Oostdijk Journal: J Clin Endocrinol Metab Date: 2016-02-03 Impact factor: 5.958